GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (WBO:EVT) » Definitions » EV-to-FCF

Evotec SE (WBO:EVT) EV-to-FCF : -24.81 (As of Apr. 30, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Evotec SE EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Evotec SE's Enterprise Value is €1,735.1 Mil. Evotec SE's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-70.0 Mil. Therefore, Evotec SE's EV-to-FCF for today is -24.81.

The historical rank and industry rank for Evotec SE's EV-to-FCF or its related term are showing as below:

WBO:EVT' s EV-to-FCF Range Over the Past 10 Years
Min: -1140.98   Med: 26.79   Max: 277260.92
Current: -24.51

During the past 13 years, the highest EV-to-FCF of Evotec SE was 277260.92. The lowest was -1140.98. And the median was 26.79.

WBO:EVT's EV-to-FCF is ranked worse than
100% of 510 companies
in the Drug Manufacturers industry
Industry Median: 22.655 vs WBO:EVT: -24.51

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-30), Evotec SE's stock price is €9.715. Evotec SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.390. Therefore, Evotec SE's PE Ratio for today is At Loss.


Evotec SE EV-to-FCF Historical Data

The historical data trend for Evotec SE's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE EV-to-FCF Chart

Evotec SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 350.50 -91.17 2,173.73 113.87 -21.05

Evotec SE Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.57 113.87 -21.96 -40.06 -21.05

Competitive Comparison of Evotec SE's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evotec SE's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Evotec SE's EV-to-FCF falls into.



Evotec SE EV-to-FCF Calculation

Evotec SE's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1735.126/-69.95
=-24.81

Evotec SE's current Enterprise Value is €1,735.1 Mil.
Evotec SE's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-70.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evotec SE  (WBO:EVT) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Evotec SE's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=9.715/-0.390
=At Loss

Evotec SE's share price for today is €9.715.
Evotec SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.390.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Evotec SE EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Evotec SE's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Evotec SE (WBO:EVT) Business Description

Address
Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419
Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally and through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.

Evotec SE (WBO:EVT) Headlines